Journal of autism and childhood schizophrenia

, Volume 2, Issue 4, pp 343–358

Response to triiodothyronine and dextroamphetamine: A study of preschool schizophrenic children

Authors

  • Magda Campbell
    • New York University Medical Center
  • Barbara Fish
    • New York University Medical Center
  • Raphael David
    • New York University Medical Center
  • Theodore Shapiro
    • New York University Medical Center
  • Patrick Collins
    • New York University Medical Center
  • Celedonia Koh
    • New York University Medical Center
Article

DOI: 10.1007/BF01538168

Cite this article as:
Campbell, M., Fish, B., David, R. et al. J Autism Dev Disord (1972) 2: 343. doi:10.1007/BF01538168

Abstract

A controlled study of triiodothyronine (T3), a hormone with CNS effects and stimulating properties, is reported in detail and discussed. Twelve of the 16 subjects (13 boys and 3 girls ranging in age from 3 to 6 years) were psychotic (10 schizophrenic and 2 autistic), 2 had chronic organic brain syndromes (Turner's and Klinefelter's, both with withdrawing reaction) and 2 were nonpsychotic (withdrawing and hyperkinetic reactions). Optimal daily doses of T3 ranged from 12.5 to 75 mcg, while those of dextroamphetamine, used as control, from 1.25 to 10 mg. Nonblind evaluations indicated marked improvement on T3 in 11 children, slight in 3, and deterioration in one. Blind ratings indicated statistically significant improvement in overall symptomatology (p⩽0.01). While dextroamphetamine yielded poor responses in all diagnostic categories, T3 had antipsychotic and stimulating effects. T3 is viewed as an agent that is potentially effective in the treatment of childhood schizophrenia.

Copyright information

© Scripta Publishing Company 1972